UBS Group AG Sells 256,313 Shares of Taysha Gene Therapies, Inc. $TSHA

UBS Group AG trimmed its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 40.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 383,043 shares of the company’s stock after selling 256,313 shares during the quarter. UBS Group AG’s holdings in Taysha Gene Therapies were worth $2,107,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of TSHA. Adage Capital Partners GP L.L.C. bought a new stake in shares of Taysha Gene Therapies during the second quarter worth approximately $11,178,000. Barclays PLC raised its stake in shares of Taysha Gene Therapies by 1,042.8% during the third quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock worth $16,834,000 after buying an additional 4,697,611 shares during the last quarter. MPM Bioimpact LLC bought a new stake in shares of Taysha Gene Therapies during the second quarter worth approximately $6,823,000. Vestal Point Capital LP raised its stake in shares of Taysha Gene Therapies by 83.3% during the third quarter. Vestal Point Capital LP now owns 5,500,000 shares of the company’s stock worth $17,985,000 after buying an additional 2,500,000 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Taysha Gene Therapies by 17.9% during the third quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company’s stock worth $42,018,000 after buying an additional 1,955,486 shares during the last quarter. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Stock Up 2.9%

Shares of NASDAQ:TSHA opened at $5.75 on Thursday. Taysha Gene Therapies, Inc. has a 52 week low of $2.25 and a 52 week high of $7.30. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.04 and a current ratio of 14.04. The company has a market capitalization of $1.65 billion, a PE ratio of -15.13 and a beta of 1.25. The company has a 50 day moving average price of $5.46 and a two-hundred day moving average price of $5.05.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its earnings results on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Analysts forecast that Taysha Gene Therapies, Inc. will post -0.47 earnings per share for the current year.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the completion of the sale, the insider owned 1,136,410 shares of the company’s stock, valued at $5,068,388.60. This represents a 14.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.78% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on TSHA. Wall Street Zen downgraded shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Truist Financial raised shares of Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Finally, Needham & Company LLC upped their target price on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Taysha Gene Therapies presently has an average rating of “Buy” and an average target price of $11.64.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.